Cornell launches clinical trial of once-weekly GLP-1 therapy for feline weight management Kelly King Cornell University is enrolling client-owned cats in an 11-week trial of AKS-562c, a once-weekly GLP-1 Fc-fusion candidate designed to reduce appetite and produce clinically meaningful weight loss while closely monitoring safety and tolerability
September 1, 2024: Kentucky Woman Files Lawsuit Alleging Ozempic Caused Gastroparesis On August 27, 2024, a 43-year-old Kentucky woman filed an Ozempic lawsuit, alleging that the GLP-1 drugs caused her gastroparesis, or stomach paralysis
Idiopathic Male Infertility Unfortunately, many men seen for infertility and abnormal semen analyses have no obvious cause for their condition
Injecting a bacterially contaminated solution can cause injection site infections ranging from mild redness to serious abscesses, systemic infections if bacteria enter the bloodstream, and immune reactions that mimic allergic responses
Dulaglutide (Trulicity), liraglutide (Victoza), and tirzepatide (Mounjaro, a dual GIP/GLP-1 receptor agonist) have similar mechanisms of action but differ in their pharmacokinetic profiles and dosing schedules